VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Thursday,Benzinga reports. D. Boral Capital currently has a $5.00 price target on the stock.

Several other research firms have also issued reports on VNRX. Jones Trading upgraded shares of VolitionRx to a “strong-buy” rating and set a $3.00 target price for the company in a report on Tuesday, June 10th. Wall Street Zen began coverage on shares of VolitionRx in a report on Thursday, May 15th. They set a “sell” rating for the company. Finally, HC Wainwright began coverage on shares of VolitionRx in a report on Tuesday, April 8th. They set a “buy” rating and a $2.50 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, VolitionRx presently has a consensus rating of “Moderate Buy” and an average target price of $3.50.

VolitionRx Stock Down 0.2%

Shares of NYSE:VNRX opened at $0.68 on Thursday. VolitionRx has a 52 week low of $0.40 and a 52 week high of $0.94. The stock has a market capitalization of $70.19 million, a P/E ratio of -1.87 and a beta of 1.20. The firm has a fifty day simple moving average of $0.63 and a two-hundred day simple moving average of $0.59.

Institutional Trading of VolitionRx

Several large investors have recently bought and sold shares of VNRX. Two Sigma Securities LLC acquired a new stake in VolitionRx during the 4th quarter valued at approximately $29,000. Northern Trust Corp lifted its stake in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Millennium Management LLC acquired a new stake in VolitionRx during the 4th quarter valued at approximately $36,000. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after acquiring an additional 60,209 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.